Media headlines about Avinger (NASDAQ:AVGR) have trended somewhat positive on Monday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Avinger earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave press coverage about the medical device company an impact score of 45.8140261702738 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Separately, Zacks Investment Research lowered shares of Avinger from a “buy” rating to a “hold” rating in a report on Thursday. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $3.42.
Shares of Avinger (NASDAQ AVGR) traded down $0.01 on Monday, hitting $0.19. 609,400 shares of the stock were exchanged, compared to its average volume of 1,318,378. The company has a market cap of $6.15 and a price-to-earnings ratio of -0.09. Avinger has a 1 year low of $0.17 and a 1 year high of $3.40.
Avinger (NASDAQ:AVGR) last announced its quarterly earnings data on Thursday, November 9th. The medical device company reported ($0.43) earnings per share for the quarter. analysts expect that Avinger will post -1.83 earnings per share for the current fiscal year.
In related news, Chairman John B. Ph D. Md Simpson sold 454,584 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $0.27, for a total transaction of $122,737.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider John B. Ph D. Md Simpson sold 1,074,130 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $0.25, for a total transaction of $268,532.50. The disclosure for this sale can be found here. Insiders own 4.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/15/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-avinger-avgr-stock-price.html.
Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.